Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia
-
Published:2024-04
Issue:4
Volume:11
Page:e245-e246
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Reference10 articles.
1. Acute myeloid leukaemia;DiNardo;Lancet,2023
2. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions;Short;Am J Hematol,2022
3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial;DiNardo;Lancet Haematol,2020
4. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial;Lübbert;Lancet Haematol,2023
5. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med,2020